194 related articles for article (PubMed ID: 34972830)
21. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
22. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy.
Joehlin-Price AS; Komforti MK; Ladwig NR; Devine P; Hoyle C; McCoy L; Sprague C; Astbury C; Hoda R; Chen YY; Garg K
Am J Surg Pathol; 2023 May; 47(5):580-588. PubMed ID: 36939053
[TBL] [Abstract][Full Text] [Related]
23. Oncogene alterations in endometrial carcinosarcomas.
Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
[TBL] [Abstract][Full Text] [Related]
24. Androgen Receptor Immunohistochemical Expression in Undifferentiated/Dedifferentiated Endometrial Carcinoma.
Cao J; Hacking S; Chavarria-Bernal HD; Bhuiya TA; Khutti S
Int J Gynecol Pathol; 2022 Jan; 41(1):28-34. PubMed ID: 33399351
[TBL] [Abstract][Full Text] [Related]
25. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
Clin Cancer Res; 2024 Jun; 30(11):2461-2474. PubMed ID: 38536067
[TBL] [Abstract][Full Text] [Related]
26. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
28. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract][Full Text] [Related]
29. Decreased HER2 expression in endometrial cancer following anti-HER2 therapy.
Chui MH; Brown DN; Da Cruz Paula A; da Silva EM; Momeni-Boroujeni A; Reis-Filho JS; Zhang Y; Makker V; Ellenson LH; Weigelt B
J Pathol; 2024 Feb; 262(2):129-136. PubMed ID: 38013631
[TBL] [Abstract][Full Text] [Related]
30. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
[TBL] [Abstract][Full Text] [Related]
31. HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Buza N
Int J Gynecol Pathol; 2021 Jan; 40(1):17-23. PubMed ID: 33290351
[TBL] [Abstract][Full Text] [Related]
32. HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology.
Jenkins TM; Cantrell LA; Stoler MH; Mills AM
Am J Surg Pathol; 2022 Apr; 46(4):435-442. PubMed ID: 35125452
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
34. Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas.
Jones NL; Xiu J; Chatterjee-Paer S; Buckley de Meritens A; Burke WM; Tergas AI; Wright JD; Hou JY
Int J Cancer; 2017 Mar; 140(6):1396-1404. PubMed ID: 27905110
[TBL] [Abstract][Full Text] [Related]
35. Molecular Genetics of Endometrial Carcinoma.
Bell DW; Ellenson LH
Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
Fleming GF; Sill MW; Darcy KM; McMeekin DS; Thigpen JT; Adler LM; Berek JS; Chapman JA; DiSilvestro PA; Horowitz IR; Fiorica JV
Gynecol Oncol; 2010 Jan; 116(1):15-20. PubMed ID: 19840887
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic Variation in p53 Usage for Endometrial Carcinoma Diagnosis: Implications for Molecular Subtyping.
Baniak N; Gilks CB; DeCoteau J; Kinloch M
Int J Gynecol Pathol; 2020 Nov; 39(6):514-521. PubMed ID: 31569187
[TBL] [Abstract][Full Text] [Related]
38. HER2 in uterine serous carcinoma: Current state and clinical perspectives.
Navarro Sanchez JM; Finkelman BS; Turner BM; Katerji H; Wang X; Varghese S; Wang T; Peng Y; Hicks DG; Zhang H
Am J Clin Pathol; 2023 Oct; 160(4):341-351. PubMed ID: 37267036
[TBL] [Abstract][Full Text] [Related]
39. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
Urick ME; Bell DW
Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
[TBL] [Abstract][Full Text] [Related]
40. miR-497-5p Decreased Expression Associated with High-Risk Endometrial Cancer.
Fridrichova I; Kalinkova L; Karhanek M; Smolkova B; Machalekova K; Wachsmannova L; Nikolaieva N; Kajo K
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
